Effect of stereo and regiochemistry towards wild and multidrug resistant HIV-1 virus: Viral potency of chiral PETT derivatives

Biochemical Pharmacology

Volumn 67, Issue 10, 2004, Pages 1933-1946

  Venkatachalam, Taracad K ^a   Mao, Chen ^a   Uckun, Fatih M ^a  

^a PARKER HUGHES INSTITUTE   (United States)

Author keywords

HIV; Multidrug resistance; Non nucleoside inhibitors; Regiochemistry; Stereochemistry; Thiourea

Indexed keywords

CAPRAVIRINE; DELAVIRDINE; EFAVIRENZ; ETRAVIRINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; THIOUREA DERIVATIVE; TROVIRDINE;

ARTICLE; CHIRALITY; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENCY; DRUG SYNTHESIS; ENANTIOMER; EVALUATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MOLECULAR MODEL; MULTIDRUG RESISTANCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; STEREOCHEMISTRY; STEREOSPECIFICITY; SUBSTITUTION REACTION; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE; WILD TYPE;

ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG STABILITY; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; TRIAZOLES;

EID: 2342502598     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2004.01.019     Document Type: Article

References (31)

1. Levy J.A. Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev. 57:1993;183-289
2. Greene W.C. The molecular biology of human immunodeficiency virus type 1 infections. N. Engl. J. Med. 324:1991;308-317
3. De Clercq E. HIV inhibitors targeted at the reverse transcriptase. AIDS Res. Hum. Retroviruses. 8:1992;119-134
4. Mitsuya H., Yarchoan R., Broder S. Molecular targets for AIDS therapy. Science. 249:1990;1533-1544
5. Hajos G., Riedi Z., Molnar J., Szabo D. Non-nucleoside reverse transcriptase inhibitors. Drugs Future. 25:2000;47-62
6. Jonckheere H., Anne J., De Clercq E. The HIV-1 reverse transcription (RT) process as target for RT inhibitors. Med. Res. Rev. 20:2000;129-154
7. Satcher D., Gayle H.D., DeCock K.M., Ward J.M., Fleming P.L., Metler P.R., et al. HIV/AIDS surveillance report, US HIV and AIDS cases reported through June 1997. HIV/AIDS Surveill Rep. 9:1997;1-37
8. Goldschmidt R.H., Dong B.J. Treatment of AIDS and HIV-related conditions. J. Am. Board Farm. Pract. 10:1997;144-167
9. Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, et al. Novel four-drug salvage treatment regimens after failure of a HIV-1 protease inhibitor. J Infect Dis 1999;179:1375-81.
10. Ren J., Eanouf R., Hopkins A., Ross C., Jones Y., Stammers D., et al. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO lessons for inhibitor design. Structure. 3:1995;915-926
11. Ren J., Eanouf R., Garman E., Somers D., Ross C., Kirby I., et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat. Struct. Biol. 2:1995;293-302
12. Ding J., Das K., Moereels H., Koymans L., Andries K., Janssen P.A., et al. Structure of HIV-1 RT/TIBOR 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat. Struct. Biol. 2:1995;407-415
13. Bell F.W., Cantrell A.S., Hogberg M., Jaskunas S.R., Johansson N.G., Jordan C.L., et al. Phenethylthiazolylthiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs. J. Med. Chem. 38:1995;4929-4936
14. Cantrell A.S., Engelhardt P., Hogberg M., Jaskunas S.R., Johansson N.G., Jordan C.L., et al. Phenethylthiazolyl thiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs. J. Med. Chem. 39:1996;4261-4274
15. Mao C., Vig R., Venkatachalam T.K., Sudbeck E.A., Uckun F.M. Structure-based design of N-[2-(1-piperidinylethyl)]-N′-[2-(5- bromopyridyl)]-thiourea and N-[2-(1-pieperizinylethyl)]-N′-[2-(5- bromopyridyl)]-thiourea as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. 8:1998;2213-2218
16. Mao C., Sudbeck E.A., Venkatachalam T.K., Uckun F.M. Rational design of N-[2-(2, 5-dimethoxyphenethyl)]-N′-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus. Bioorg. Med. Chem. Lett. 9:1999;1593-1598
17. Mao C., Sudbeck E.A., Venkatachalam T.K., Uckun F.M. Structure based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase. Biochem. Pharmacol. 60:2000;1251-1265
18. Uckun F.M., Mao C., Pendergrass S., Maher D., Zhu D., Tuel-Ahlgren L., et al. N-[2-(1-Cyclohexenyl) ethyl]-N′-[2-(5-bromopyridyl)]-thiourea and N′-[2-(1-cyclohexenyl)ethyl]-N′-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1. Bioorg. Med. Chem. Lett. 9:1999;2721-2726
19. Sudbeck E.A., Mao C., Vig R., Venkatachalam T.K., Tuel-Ahlgren L., Uckun F.M. Structure based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptase. Antimicro Agents Chemother. 19:1998;225-233
20. Venkatachalam T.K., Sudbeck E.A., Mao C., Uckun F.M. Stereochemistry of halopyridyl and thiazolyl thiourea compounds is a major determinant of their potency as non-nucleoside inhibitors of HIV-1 reverse transcriptase. Bioorg. Med. Chem. Lett. 10:2000;2071-2074
21. Venkatachalam T.K., Mao C., Uckun F.M. Stereochemistry as a major determinant of the anti-HIV activity of chiral naphthyl thiourea compounds. Antivir. Chem. Chemther. 12:2001;213-221
22. Zarling J.M., Moran P.A., Haffar O., Sias J., Richman D.D., Spina C.A., et al. Inhibition of HIV replication by pokeweed antiviral protein targeted to CD4+ cells by monoclonal antibodies. Nature. 347:1990;92-95
23. Uckun F.M., Chelstrom L.M., Tuel-Ahlgren L., Dirbirdik I., Irvin J.D., Chandan-Langlie M., et al. TXU (anti-CD7)-pokeweed antiviral protein as a potent inhibitor of human immunodeficiency virus. Antimicrob. Agents Chemother. 42:1998;383-388
24. Franchetti P., Sheikha A.G., Cappellacci L., Grifantini M., De Montis A., Piras G., et al. Synthesis and antiviral activity of 8-aza analogs of chiral [2-(phosphonomethoxy)propyl] guanines. J. Med. Chem. 38:1995;4007-4013
25. Chen C.L., Uckun F.M. Evaluation of the pharmacokinetic features and tissue distribution of the potent nonnucleoside inhibitor of HIV-1 reverse transcriptase, N-[2-(2-flurophenethyl)]-N′[2-(5-bromopyridyl)]-thiourea (HI-240) with an analytical HPLC method. Pharm. Res. 16:1999;1226-1232
26. Chen C.L., Venkatachalam T.K., Waurzyniak B., Chelstrom L., Uckun F.M. In vivo toxicity, pharmacokinetic features and tissue distribution of N-[2-(2, 5-dimethoxyphenylethyl)]-N′-[2-(5-bromopyridyl)]-thiourea (HI-236), a potent nonnucleoside inhibitor of HIV-1 reverse transcriptase. Arzneimittelforschung. 51:2001;574-581
27. Young S.D., Britcher S.F., Tran L.O., Payne L.S., Lumma W.C., Lyle T.A., et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type-1 reverse transcriptase. Antimicrob. Agents Chemother. 39:1995;2602-2605
28. Fujiwawra T., Sato A., el-Faarash M., Miki S., Abe K., Isaka Y., et al. S-1153 inhibits the replication of known drug-resistant strains of human immunodeficiency virus type-1. Antimicrob. Agents Chemother. 42:1998;1340-1345
29. Blagovic M.U., Rives J.T., Jorgensen W.L. Validation of a model for the complex of HIV reverse transcriptase with nonnucleoside inhibitor TMC 125. J. Am. Chem. Soc. 125:2003;6016-6017
30. Lodovici D.W., De Corte B.L., Kukla M.J., Ye H., Ho C.Y., Lichtenstein M.A., et al. Evolution of anti-HIV drug candidates. Part 2: Diaryltriazine (DATA) analogues. Bioorg. Med. Chem. Lett. 11:2001;2235-2239
31. Cohen J. Special news report, HIV/AIDS. Science. 296:2002;2320-2324